Alleviating Effects of AS1892802, a Rho Kinase Inhibitor, on Osteoarthritic Disorders in Rodents

被引:19
|
作者
Takeshita, Nobuaki [1 ]
Yoshimi, Eiji [1 ]
Hatori, Chie [1 ]
Kumakura, Fumiyo [1 ]
Seki, Nobuo [1 ]
Shimizu, Yasuaki [1 ]
机构
[1] Astellas Pharma Inc, Pharmacol Res Labs, Tsukuba, Ibaraki 3058585, Japan
关键词
osteoarthritis; Rho kinase inhibitor; cartilage; pain; inflammation; DEGENERATIVE JOINT DISEASE; CHONDROGENIC DIFFERENTIATION; NEUROPATHIC PAIN; PROTEIN-KINASE; MOUSE KNEE; RAT MODELS; ACTIVATION; INTERLEUKIN-1-BETA; EXPRESSION; MORPHOLOGY;
D O I
10.1254/jphs.10319FP
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of AS 1892802, a selective Rho-associated coiled coil kinase (ROCK) inhibitor, on knee cartilage damage and pain behavior were examined in a rat model of osteoarthritis (OA). Monoiodoacetate (MIA) was intraarticularly injected into the right knee joints of rats. ROCK I and II mRNA levels increased in knee joints of MIA-injected rats. Our newly synthesized ROCK inhibitor, AS1892802, was injected into the ipsilateral knee or administered p.o. for 3 weeks. The compound dose-dependently and significantly inhibited of cartilage damage in the tibial plateau in a dose-dependent manner and decreased the weight distribution deficit associated with MIA injection. In addition, the compound also inhibited bradykinin induced pain responses in normal rats. In vitro, the compound could induce chondrocyte differentiation in a chondrogenic cell line and significantly inhibited IL-1 beta- or bradykinin-induced prostaglandin E-2 production in a synovial cell line. AS1892802 prevents cartilage damage induced by MIA and has analgesic effects in rat pain models, suggesting that AS1892802 may be clinically useful for the treatment of OA.
引用
收藏
页码:481 / 489
页数:9
相关论文
共 46 条
  • [21] Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase
    Kast, R.
    Schirok, H.
    Figueroa-Perez, S.
    Mittendorf, J.
    Gnoth, M. J.
    Apeler, H.
    Lenz, J.
    Franz, J. K.
    Knorr, A.
    Huetter, J.
    Lobell, M.
    Zimmermann, K.
    Muenter, K.
    Augstein, K. H.
    Ehmke, H.
    Stasch, J. P.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (07) : 1070 - 1080
  • [22] Evaluation of Rho kinase inhibitor effects on neuroprotection and neuroinflammation in an ex-vivo retinal explant model
    Reboussin, Elodie
    Bastelica, Paul
    Benmessabih, Ilyes
    Cordovilla, Arnaud
    Delarasse, Cecile
    Reaux-Le Goazigo, Annabelle
    Brignole-Baudouin, Francoise
    Olmiere, Celine
    Baudouin, Christophe
    Buffault, Juliette
    Melik Parsadaniantz, Stephane
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2024, 12 (01):
  • [23] Neuroprotective Effects of Fasudil, a Rho-Kinase Inhibitor, After Spinal Cord Ischemia and Reperfusion in Rats
    Ohbuchi, Masahiko
    Kimura, Tetsu
    Nishikawa, Toshiaki
    Horiguchi, Takashi
    Fukuda, Masayuki
    Masaki, Yoko
    ANESTHESIA AND ANALGESIA, 2018, 126 (03) : 815 - 823
  • [24] Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension
    Fujita, Hiroshi
    Fukumoto, Yoshihiro
    Saji, Kenya
    Sugimura, Koichiro
    Demachi, Jun
    Nawata, Jun
    Shimokawa, Hiroaki
    HEART AND VESSELS, 2010, 25 (02) : 144 - 149
  • [25] Effects of Fasudil, a Rho-Associated Protein Kinase Inhibitor, on Optic Nerve Head Blood Flow in Rabbits
    Sugiyama, Tetsuya
    Shibata, Maho
    Kajiura, Sumiko
    Okuno, Takashi
    Tonari, Masahiro
    Oku, Hidehiro
    Ikeda, Tsunehiko
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2011, 52 (01) : 64 - 69
  • [26] Acute Effects of Rho-Kinase Inhibitor Fasudil on Pulmonary Arterial Hypertension in Patients With Congenital Heart Defects
    Xiao, Jia-wang
    Zhu, Xian-yang
    Wang, Qi-guang
    Zhang, Duan-zhen
    Cui, Chun-sheng
    Zhang, Po
    Chen, Huo-yuan
    Meng, Li-li
    CIRCULATION JOURNAL, 2015, 79 (06) : 1342 - 1348
  • [27] Pharmacological characterization of a highly selective Rho kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension
    Cantoni, Silvia
    Cavalli, Stefano
    Pastore, Fiorella
    Accetta, Alessandro
    Pala, Daniele
    Vaccaro, Fabio
    Cesari, Nicola
    De Logu, Francesco
    Nassini, Romina
    Villetti, Gino
    Facchinetti, Fabrizio
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 850 : 126 - 134
  • [28] Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
    Satoh, Shin-ichi
    Ikegaki, Ichiro
    Kawasaki, Koh
    Asano, Toshio
    Shibuya, Masato
    CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (05) : 758 - 765
  • [29] Rho-Kinase Inhibitor Prevents Bleomycin-Induced Injury in Neonatal Rats Independent of Effects on Lung Inflammation
    Lee, Alvin H.
    Dhaliwal, Rupinder
    Kantores, Crystal
    Ivanovska, Julijana
    Gosal, Kiran
    McNamara, Patrick J.
    Letarte, Michelle
    Jankov, Robert P.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2014, 50 (01) : 61 - 73
  • [30] Vitamin A-coupled liposomal Rho-kinase inhibitor ameliorates liver fibrosis without systemic adverse effects
    Okimoto, Sho
    Kuroda, Shintaro
    Tashiro, Hirotaka
    Kobayashi, Tsuyoshi
    Taogoshi, Takanori
    Matsuo, Hiroaki
    Ohdan, Hideki
    HEPATOLOGY RESEARCH, 2019, 49 (06) : 663 - 675